Olaparib: Difference between revisions
No edit summary |
Michal Harel (talk | contribs) No edit summary |
||
| (10 intermediate revisions by one other user not shown) | |||
| Line 1: | Line 1: | ||
<StructureSection load='' size='340' side='right' caption=' | <StructureSection load='' size='340' side='right' caption='Olaparib' scene='10/1001156/Cv/1'> | ||
Olaparib, sold under the brand name Lynparza, is a medication for the maintenance treatment of BRCA-mutated advanced ovarian cancer in adults. It is a PARP inhibitor, inhibiting poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair. It acts against cancers in people with hereditary BRCA1 or BRCA2 mutations, which include some ovarian, breast, and prostate cancers. See also [https://en.wikipedia.org/wiki/Olaparib Olaparib]. | Olaparib, sold under the brand name Lynparza, is a medication for the maintenance treatment of BRCA-mutated advanced ovarian cancer in adults (see [[BRCA]]). It is a PARP inhibitor, inhibiting [[Poly (ADP-ribose) polymerase|poly ADP ribose polymerase]] (PARP), an enzyme involved in DNA repair. It acts against cancers in people with hereditary BRCA1 or BRCA2 mutations, which include some ovarian, breast, and prostate cancers.<ref name="a7">PMID:19553641</ref> See also [https://en.wikipedia.org/wiki/Olaparib Olaparib]. | ||
Olaparib acts as an inhibitor of the enzyme poly ADP ribose polymerase (PARP), and is termed a PARP inhibitor. BRCA1/2 mutations may be genetically predisposed to development of some forms of cancer, and may be resistant to other forms of cancer treatment. However, these cancers sometimes have a unique vulnerability, as the cancer cells have increased reliance on PARP to repair their DNA and enable them to continue dividing. This means that drugs which selectively inhibit PARP may be of benefit if the cancers are susceptible to this treatment.<ref name="a14">PMID:18800822</ref> | |||
<scene name='10/1001156/Overall/1'>Poly [ADP-ribose] polymerase 2 in complex with Olaparib</scene> ([[4tvj]]). | |||
<scene name='10/1001156/Binding_site/2'>Olaparib binding site</scene>. Water molecules are shown as red spheres. | |||
See also: | |||
*[[Mutations in BRCA1/BARD1 RING-domain heterodimer]] | |||
*[[Mutations in Brca1 BRCT Domains]] | |||
*[[RING Finger Domain of BRCA1 and BARD1 Heterodimer]] | |||
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> | ||